1. Long-Term Safety of Oral Transmucosal Fentanyl Citrate for Breakthrough Cancer Pain 
Richard Payne, MD, Paul Coluzzi, MD, Lowell Hart, MD, Mary Simmonds, MD, Alan Lyss, MD, Richard Rauck, MD, Robert Berris, MD, Michael A Busch, PhD, Earl Nordbrook, PhD, Diane B Loseth, RN, MSN, Russell K Portenoy, MD 
Journal of Pain and Symptom Management 
Volume 22, Issue 1, Pages (July 2001)
DOI: /S (01)

2. Fig. 1 Number of Days Patients Used OTFC (n = 151)
Journal of Pain and Symptom Management  , DOI: ( /S (01) )

3. Fig. 2 Number of OTFC Units Per Patient (n = 151)
Journal of Pain and Symptom Management  , DOI: ( /S (01) )

4. Fig. 3
Initial Dose of OTFC in Relation to Initial Dose of Around-the-Clock Medication for Patients Using Transdermal Fentanyl (n = 53) and Patients Using Oral Opioids (n = 99)
Journal of Pain and Symptom Management  , DOI: ( /S (01) )